Inogen (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction on Tuesday, April 17th. The shares were sold at an average price of $139.82, for a total value of $139,820.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $139,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of NASDAQ:INGN opened at $141.08 on Friday. The firm has a market capitalization of $2,992.87, a PE ratio of 109.36, a price-to-earnings-growth ratio of 3.93 and a beta of 1.03. Inogen has a 52 week low of $78.30 and a 52 week high of $144.05.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. The business had revenue of $63.79 million during the quarter, compared to the consensus estimate of $62.01 million. Inogen had a return on equity of 13.47% and a net margin of 8.42%. analysts expect that Inogen will post 1.6 EPS for the current year.

Several large investors have recently made changes to their positions in INGN. Lenox Wealth Advisors Inc. purchased a new stake in Inogen during the fourth quarter valued at about $100,000. Steward Partners Investment Advisory LLC grew its position in Inogen by 1,000.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock valued at $130,000 after acquiring an additional 1,000 shares during the period. Simplex Trading LLC purchased a new stake in Inogen during the fourth quarter valued at about $153,000. LS Investment Advisors LLC grew its position in Inogen by 138.6% during the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock valued at $180,000 after acquiring an additional 880 shares during the period. Finally, Everence Capital Management Inc. purchased a new stake in Inogen during the fourth quarter valued at about $208,000. 98.97% of the stock is owned by institutional investors and hedge funds.

INGN has been the subject of a number of recent analyst reports. BidaskClub downgraded Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research report on Tuesday, January 9th. Piper Jaffray raised Inogen from a “neutral” rating to an “overweight” rating in a research report on Tuesday, February 20th. Finally, Needham & Company LLC lifted their price objective on Inogen from $125.00 to $150.00 and gave the company a “strong-buy” rating in a research report on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $121.17.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Inogen (INGN) Director Sells $139,820.00 in Stock” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2018/04/22/insider-selling-inogen-ingn-director-sells-139820-00-in-stock.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.